{
  "docId": "019de071-4ec1-761e-bce7-779cb9a1fe78",
  "docSlug": "bd64755c9d094dce862ec77cfb2b1978",
  "documentTitle": "TScan Therapeutics | IPO Presentation Deck | 43 slides",
  "authorId": "tscan-therapeutics",
  "authorName": "TScan Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 43,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a before-after-bridge framework to contrast current therapy limitations with TScan's solution.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-4ec1-761e-bce7-779cb9a1fe78/12",
  "deckHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78",
  "deckJsonHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78.json",
  "deckAnchorHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Before-After Bridge",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5ce842f-817f-45cf-9256-20020e912f21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.65,
        "y": 0.5
      },
      "kind": "image",
      "text": "Patient icons",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "390a04ac-3a47-48f0-af2c-f2e17b454947",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.15,
        "y": 0.5
      },
      "kind": "image",
      "text": "Patient icons",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9379d288-edfa-4ee8-8a3b-31e10749b93d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.53,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "TScan's platforms overcome current challenges with multiplexed TCR-T. TCR-T can address majority of patients. TCR-T can infiltrate solid tumors. TScan platforms enable discovery of novel targets for multiplexed TCR-T.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13e891ff-5e56-40c1-8340-a6ef77095889",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.07,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Most solid tumor patients do not respond to current therapies. Checkpoint / TIL therapy response limited to subset of patients. CAR-T efficacy limited to liquid tumors. TCR-T provides a potential solution for solid tumors but is limited by available targets.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "338563fd-56db-4ed4-8a08-a7392b161566",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "TScan positioned to overcome solid tumor challenges using multiplexed TCR-T therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a381768d-cdb2-43ac-81fc-fd1a940485ee",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "8faccd7b-bdcc-4f79-b81f-c83b56da00c7",
      "evidence": "Before-After Bridge",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "5290afa2-4dd2-46f1-9edb-dd5b7ccef9c2",
      "evidence": "Contrasts current therapy limitations with TScan's solution.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "b1431f82-1cfa-496e-bf51-8dcfe1b966ab",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents a comprehensive overview of TScan Therapeutics' solution, including its proprietary TCR-T pipeline and TargetScan platform.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "af0b626c-c83f-46d7-8946-9b828a4fc0e6",
      "evidence": "The document presents a comprehensive overview of TScan Therapeutics' solution, including its proprietary TCR-T pipeline and TargetScan platform.",
      "position": 1,
      "objective": "Why is TScan Therapeutics' multiplexed TCR-T therapy a good solution for patients with cancer?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}